Distribuzione geografica
Continente #
NA - Nord America 7.084
EU - Europa 5.071
AS - Asia 1.947
AF - Africa 321
SA - Sud America 22
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 14.459
Nazione #
US - Stati Uniti d'America 7.069
GB - Regno Unito 1.814
CN - Cina 787
SE - Svezia 783
VN - Vietnam 640
DE - Germania 621
IT - Italia 605
IN - India 296
UA - Ucraina 247
IE - Irlanda 212
RU - Federazione Russa 205
FR - Francia 200
ZA - Sudafrica 129
EE - Estonia 123
TG - Togo 110
JP - Giappone 79
JO - Giordania 68
CH - Svizzera 65
BG - Bulgaria 64
NG - Nigeria 39
BE - Belgio 32
FI - Finlandia 29
CI - Costa d'Avorio 27
GR - Grecia 22
IR - Iran 18
SC - Seychelles 15
CA - Canada 14
NL - Olanda 13
TR - Turchia 12
AT - Austria 9
BR - Brasile 9
LB - Libano 9
AU - Australia 8
HK - Hong Kong 8
CL - Cile 7
RO - Romania 7
KR - Corea 6
AE - Emirati Arabi Uniti 4
CZ - Repubblica Ceca 4
PL - Polonia 4
SG - Singapore 4
AR - Argentina 3
EU - Europa 3
ID - Indonesia 3
IL - Israele 3
NO - Norvegia 3
EC - Ecuador 2
ES - Italia 2
IQ - Iraq 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
KZ - Kazakistan 1
LV - Lettonia 1
MA - Marocco 1
MX - Messico 1
MY - Malesia 1
PH - Filippine 1
PK - Pakistan 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 14.459
Città #
Southend 1.689
Fairfield 1.029
Chandler 793
Ashburn 578
Woodbridge 543
Houston 495
Wilmington 486
Seattle 470
Dong Ket 406
Cambridge 346
Princeton 327
Ann Arbor 316
Dublin 212
Nanjing 160
Westminster 145
Padova 131
Jacksonville 130
Beijing 111
Lomé 110
Bologna 108
Berlin 92
Saint Petersburg 73
Tokyo 69
Amman 68
New York 67
Sofia 64
Jinan 63
Shenyang 62
Turin 61
Bern 59
San Diego 54
Nanchang 53
Hebei 51
Changsha 47
Boardman 45
Falls Church 45
Jiaxing 41
Abeokuta 39
Bremen 33
Brussels 32
Medford 32
Redmond 32
Tianjin 29
Helsinki 28
Milan 28
Abidjan 27
Mülheim 27
Dearborn 25
Florence 25
Norwalk 25
Des Moines 21
Haikou 20
Zhengzhou 19
Taizhou 17
Mahé 15
Mountain View 15
Redwood City 15
Washington 15
Guangzhou 14
Hangzhou 13
Bühl 12
Ningbo 11
Olalla 11
Taiyuan 11
Kuban 10
Lanzhou 10
London 10
Rome 10
Verona 10
Istanbul 9
San Venanzo 9
Toronto 9
Andover 8
Kunming 8
Abano Terme 7
Forlì 7
Los Angeles 7
Paris 7
Frankfurt Am Main 6
Pune 6
Buffalo 5
Frankfurt am Main 5
Groningen 5
Leawood 5
Phoenix 5
Piacenza 5
São Paulo 5
Zanjan 5
Athens 4
Bengaluru 4
Brescia 4
Cernusco sul Naviglio 4
Chengdu 4
Chiyoda-ku 4
Clearwater 4
Farra d'Isonzo 4
Hong Kong 4
Muizenberg 4
Negrar 4
San Francisco 4
Totale 10.411
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 320
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 210
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 209
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 204
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 198
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 192
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 190
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 161
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 160
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 159
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 159
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 158
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 156
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 156
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 152
Consensus conference on the management of tumor lysis syndrome. 149
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 147
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 145
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 145
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 132
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 129
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 129
Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50? 123
null 122
Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. 122
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 122
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 121
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. 120
Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib. 118
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 117
In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. 117
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 117
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 116
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 116
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 115
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 114
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 112
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 112
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 112
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 108
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 107
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 107
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia 106
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 106
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 105
null 104
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 104
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 103
null 102
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 101
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 101
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 101
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 100
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 100
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 98
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 98
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 97
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 97
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 97
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 96
Diagnosis and classification of the risk 96
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 96
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 95
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 94
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 94
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. 92
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 92
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 92
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 92
Leucemia mieloide cronica: terapia molecolare 91
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 91
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 91
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 91
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 89
A review of the European LeukemiaNet recommendations for the management of CML 89
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 89
Explaining the in vitro and in vivo differences in leukemia therapy. 88
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. 88
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 87
The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up 86
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib 86
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 86
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 85
Imatinib mesylate in the treatment of hematologic malignancies. 85
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients 84
Dual tyrosine kinase inhibitors in chronic myeloid leukemia. 84
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 82
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 82
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 81
null 81
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry 81
Chronic myeloid leukemia. Drug selection in first-line therapy and beyond 80
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 80
Frontline Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Sequential Administration of Nilotinib 400 Mg Twice Daily and Imatinib 400 Mg Once Daily: a Phase 2 Multicentric Study 79
null 79
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 78
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia 78
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 78
null 77
Totale 11.385
Categoria #
all - tutte 33.100
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.100

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019400 0 0 0 0 0 0 0 0 0 156 83 161
2019/20204.396 603 119 28 270 492 426 551 558 593 303 173 280
2020/20212.273 418 181 55 82 43 83 48 140 238 95 177 713
2021/20222.815 342 88 200 256 267 170 50 177 110 192 461 502
2022/20233.149 382 505 174 384 225 225 124 173 511 64 249 133
2023/2024762 48 135 54 89 72 220 49 50 22 23 0 0
Totale 14.894